Catma Serkan, Varol Serkan
Department of Business Administration, University of South Carolina Beaufort, 1 University Blvd, Hargray 224, Bluffton, SC 29909, USA.
Department of Engineering, Management and Technology, University of Tennessee at Chattanooga, EMCS 235, 615 McCallie Ave., Chattanooga, TN 37403, USA.
Vaccines (Basel). 2021 Apr 1;9(4):318. doi: 10.3390/vaccines9040318.
Our objective was to estimate the individual willingness to pay (WTP) for a COVID-19 vaccine and evaluate its predictors in the United States. A double-bounded dichotomous choice contingent valuation with open-ended question technique was implemented based on the responses to a national survey administered during the first week of November 2020. The final sample size was 1285. The results showed that individual WTP values increased with income, whether a household member had any pre-existing condition, and perceived threat of the virus. The vaccine efficacy rate and duration of protection were found to be important factors for the respondents. The mean WTP for a vaccine with a 95 percent efficacy rate and 3-year protection (US$318.76) was approximately 35 percent greater than the vaccine with a 50 percent efficacy rate and 1-year protection (US$236.85). The initial aggregate direct benefit of the current vaccination program was estimated to be between 20 and 35.6 billion US dollars depending on the vaccine protection duration.
我们的目标是估计美国民众对新冠疫苗的个人支付意愿（WTP），并评估其预测因素。基于对2020年11月第一周进行的全国性调查的回复，采用了带有开放式问题技术的双边界二分选择条件价值评估法。最终样本量为1285。结果表明，个人支付意愿值随着收入、家庭成员是否有任何既往疾病以及对病毒的感知威胁而增加。疫苗的有效率和保护期限被发现是受访者的重要因素。有效率为95%且保护期为3年的疫苗的平均支付意愿（318.76美元）比有效率为50%且保护期为1年的疫苗（236.85美元）高出约35%。根据疫苗保护期限，当前疫苗接种计划的初始总直接收益估计在200亿至356亿美元之间。
